AEP Names Maryam S. Brown President and COO of Indiana Michigan Power
American Electric Power (AEP) has appointed Maryam S. Brown as the new president and chief operating officer of Indiana Michigan Power (I&M), effective April 27. Brown, previously CEO of Southern California Gas Company, brings over 25 years of experience in utility operations and financial management, and will report to AEP chairman, president, and CEO Bill Fehrman. She succeeds Steve Baker, who will serve as a senior advisor for the transition and AEP's nuclear development strategy in Indiana until his retirement at the end of 2026.
Former SoCalGas CEO Maryam Brown takes over Indiana Michigan Power
American Electric Power (AEP) has appointed Maryam S. Brown as president and chief operating officer of Indiana Michigan Power (I&M), effective April 27, 2026. Brown previously served as president and CEO of Southern California Gas Company and brings over 25 years of utility, regulatory, and policy experience. She will succeed Steve Baker, who will transition to a senior advisor role before retiring at the end of 2026.
Stryker agrees to acquire IVL developer Amplitude Vascular Systems
Stryker has announced its agreement to acquire Amplitude Vascular Systems (AVS), marking its entry into the rapidly growing intravascular lithotripsy (IVL) market. AVS's Pulse IVL system, designed to treat calcified peripheral artery disease, is currently undergoing pivotal trials. This acquisition follows other major medtech players like Johnson & Johnson and Boston Scientific moving into the IVL space, highlighting the market's increasing significance.
Iran war: What’s driving market sentiment?
Markets have shown resilience despite the ongoing conflict in Iran, with the S&P 500 Index remaining nearly flat after six weeks, credit spreads tightening, and volatility receding. This suggests that investors are not pricing in an endlessly spiraling conflict but rather seeking narrative closure and anticipating an eventual end. The broader macro backdrop, including resilient global leading indicators and contained inflation expectations, also continues to support risk assets.
Albemarle (ALB) Surges 5.1% Amid Market Volatility
Albemarle (ALB) stock surged 5.1% despite a broader market decline, driven by rising oil prices and geopolitical tensions. The company, a major lithium producer, benefits from its essential role in the EV battery market. However, its high price-to-sales ratio and recent insider selling suggest potential overvaluation and caution for investors.
Six Flags Entertainment (FUN) PT Lowered to $29 at Guggenheim
Guggenheim analyst Curry Baker has lowered the price target for Six Flags Entertainment (FUN) to $29. This article is a premium only piece, requiring a StreetInsider.com Premium subscription to access the full details. It indicates a revised outlook from Guggenheim regarding the valuation of Six Flags Entertainment.
EXL brings investors to Nasdaq MarketSite for May 13 strategy event
EXL (NASDAQ: EXLS) announced it will host an Investor and Analyst Day on May 13, 2026, at the NASDAQ MarketSite in Times Square, New York. CEO Rohit Kapoor and his executive team will discuss the company's data and AI strategy along with its latest solutions. A webcast replay of the event will be available for those unable to attend.
Alphabet Stock Dips in Pre-Market as AI Spending and Antitrust Pressures Weigh on GOOG
Alphabet Inc. Class C shares dipped in pre-market trading due to investor concerns over heavy AI capital spending, ongoing antitrust challenges, and broader geopolitical tensions. The company faces massive infrastructure investments to compete in the generative AI race, projected to be $175-$185 billion in 2026, which is pressuring near-term margins. Regulatory headwinds in the U.S. and Europe also remain a significant overhang, with market watchers anticipating more insights from the upcoming Q1 earnings report.
Moderna Impfstoff (Spikevax): mRNA Pivot Beyond COVID Fuels Uncertain Path
Moderna's Spikevax vaccine sales have significantly declined post-pandemic, prompting the company to pivot its mRNA technology towards new applications in cancer and other infectious diseases. This strategic shift presents both long-term potential for investors and health innovations for consumers, but also carries inherent biotech risks and financial pressures due to rising R&D costs and market competition. The article highlights the importance of monitoring regulatory approvals and pipeline developments to assess Moderna's future sustainability and stock performance.
Hubbell sets April 30 earnings release, 10 a.m. ET webcast
Hubbell (NYSE: HUBB) announced it will release its first quarter 2026 financial results before market open on April 30, 2026, followed by an Analysts' Conference Call at 10:00 AM ET on the same day. Investors can access the press release, live audio, and materials via the company's investor relations sections on its website, www.hubbell.com. Hubbell, headquartered in Shelton, CT, reported 2025 revenues of $5.8 billion.









